Reviewed, never approved
Is Ipamorelin FDA-Approved? Regulatory Status
The short answer is no. The longer answer separates a failed trial, FDA's compounding lists, and prescription access today.
The blunt version
Is ipamorelin FDA approved? No — not for any indication, not anywhere. Here's the plain story. Ipamorelin was developed in the 1990s and tested in humans, but the only proper trial (for slow bowel recovery after surgery) failed [3]. No company ever brought it across the approval line, so it has no approved medical use and no FDA-cleared label. FDA's compounding record separates a withdrawn 503A nomination from a continuing 503B Category 2 entry for ipamorelin acetate. Promise Peptides (mypromise.com) currently prescribes ipamorelin; a U.S.-licensed clinician evaluates all requests and makes a prescribing decision for each. Not every patient qualifies, care is limited to U.S. patients, and access depends on the state and treatment. Compounded medicines do not have FDA approval.
What 'never approved' actually means here
Ipamorelin has never been approved as a drug by the FDA, the EMA, or any other regulatory authority [3]. That's not a paperwork lag — it reflects that the development programs didn't deliver. The single published Phase 2 RCT (NCT00672074, 114 patients) for postoperative ileus missed its primary endpoint, with a time-to-tolerated-meal difference that didn't reach significance (25.3 h vs 32.6 h, p=0.15) [3]. No Phase 3 trial followed, and no other indication advanced that far. So the absence of approval is the absence of demonstrated efficacy, not merely an incomplete filing. "Investigational" is the accurate word; "approved" is not.
Two compounding routes, two entries
Two FDA compounding entries need separate receipts. FDA's list places ipamorelin acetate among withdrawn 503A nominations, with its safety concerns still shown; 503A is the patient-specific compounding framework. Ipamorelin acetate remains in Category 2 under 503B, the separate policy for outsourcing facilities. A withdrawn nomination does not amount to FDA clearance or a Category 1 placement. The agency reviewed ipamorelin acetate and free base at the October 29, 2024 Pharmacy Compounding Advisory Committee (PCAC) meeting. A prescription does not alter these FDA entries or the agency's safety concerns. Prescription access still depends on a licensed provider's review, and compounded medicines do not have FDA approval.
Approved-adjacent confusion to avoid
A frequent mix-up: because ipamorelin is often paired with GHRH analogs, people assume it inherits their status. It doesn't. Tesamorelin (a GHRH analog) has a real approved human indication; sermorelin had an approved-drug history. Ipamorelin is neither — it's a ghrelin-receptor agonist [1] that cleared no regulatory bar of its own. The CJC-1295 + ipamorelin combination is likewise unapproved and untested as a combination [3]. None of the stack's components lend ipamorelin an approval it never earned. When evaluating any claim, the relevant fact is ipamorelin's own record: investigated, failed its one efficacy trial, never approved.
What its status is now
For ipamorelin, prescription access starts with a licensed U.S. provider's review; not every patient qualifies. FDA's list still places ipamorelin acetate in Category 2 under 503B for outsourcing facilities, with its 503A nomination withdrawn. On top of the FDA picture, it is prohibited in sport under WADA category S2 and detectable in urine by accredited labs [7]. Two 2026 reviews classify it as an investigational GH-axis peptide with an uncertain safety profile, variable product quality, and no reproducible human efficacy for the outcomes it's marketed for [11][13]. The bottom line a reader should leave with: not FDA-approved, prescription access subject to individual review, banned in sport, and supported by a human evidence base that is thin and, where it exists, negative.